Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and T-cell engagers.

For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

New for 2026, FORGE Trials introduces an official national qualifier ecosystem, allowing teams competing in partner leagues to earn their place at the championship through structured progression. The ...

Sangamo Therapeutics has initiated a rolling Biologics License Application (BLA) submission with the U.S. Food and Drug Administration for its investigational g ...

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...

Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway ...

According to a new study published in the journal Pharmaceuticals, numerous compounds derived from cannabis may help disrupt multiple biological pathways involved in the progression of skin cancer.

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

aRenal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK ...